SMMT Stock Forecast: Summit Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Summit Therapeutics, Inc. is $32. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 36 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Summit Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (86): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Quality (23): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
SMMT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SMMT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 5 moved their price target up and 6 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Nov 2026 | Bernstein | Downgrade | Underperform | $12 → $8.30 |
| 16 Nov 2026 | Barclays | Maintains | Equal-Weight | $20 → $18 |
| 16 Nov 2026 | Citigroup | Maintains | Buy | $43 → $42 |
| 16 Nov 2026 | Evercore ISI Group | Maintains | Outperform | $34 → $33 |
| 1 Oct 2026 | Barclays | Maintains | Equal-Weight | $18 → $20 |
| 29 Sept 2026 | Citigroup | Maintains | Buy | $40 → $43 |
| 23 Sept 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 9 Sept 2026 | Jefferies | Upgrade | Buy | $15 → $25 |
| 26 Aug 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 25 Aug 2026 | Bernstein | Upgrade | Market Perform | $9.80 → $12 |
| 18 Aug 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 12 Aug 2026 | Leerink Partners | Upgrade | Market Perform | $12 → $13 |
| 24 July 2026 | Guggenheim | Maintains | Buy | $40 → $38 |
| 24 July 2026 | Stifel | Maintains | Buy | $45 → $38 |
| 23 July 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 22 May 2026 | Bernstein | Initiates | Underperform | $7.70 |
| 22 May 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 4 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 May 2026 | Piper Sandler | Maintains | Neutral | — |
| 8 Apr 2026 | Stifel | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SMMT.
This page is one stock. Monday covers all of them.
SMMT appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
SMMT vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Summit Therapeutics, Inc. returned −39.5% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
SMMT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 14.2×
- EV / EBITDA
- —
Cheaper than 5% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −220.0%
- Return on assets
- −112.0%
- Dividend yield
- —
Higher than 7% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Summit Therapeutics, Inc. has a market value of $8.5B and an enterprise value of $7.8B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$856.0M.
Diluted earnings per share, trailing twelve months: −$1.12.
Free cash flow in the twelve months to 30 June 2026: −$459.8M, after $1.4M of capital spending.
Summit Therapeutics, Inc. employs 265 people.
Data provided by Twelve Data
SMMT and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at SMMT’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Summit Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about SMMT
What is the SMMT stock price forecast for 2026-2027?
The median 12-month analyst price target for Summit Therapeutics, Inc. is $32, with estimates ranging from $8.22 to $43. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SMMT stock a buy right now?
Of the 17 analysts covering Summit Therapeutics, Inc., 11 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Summit Therapeutics, Inc. 36 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SMMT?
As at 21 Nov 2026, Summit Therapeutics, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (86 of 100).
Will SMMT stock go up?
No one can know that. What the data says: the median 12-month target from 17 analysts is $32, and Ticker Nerd's factor model ranks Summit Therapeutics, Inc. 36 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SMMT stock forecast for 2030?
No analyst covering Summit Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SMMT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8.22 to $43 over the next 12 months.
How has SMMT stock performed over the past year?
Summit Therapeutics, Inc. returned -39.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Summit Therapeutics, Inc. do?
Summit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for serious unmet medical needs. Summit Therapeutics Inc. centers its current portfolio on oncology, with ivonescimab as its lead investigational asset, a bispecific antibody designed to combine immune checkpoint blockade with anti-angiogenic activity.
About Summit Therapeutics, Inc.
Summit Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for serious unmet medical needs. Summit Therapeutics Inc. centers its current portfolio on oncology, with ivonescimab as its lead investigational asset, a bispecific antibody designed to combine immune checkpoint blockade with anti-angiogenic activity. The company is advancing ivonescimab in multiple late-stage clinical programs for non-small cell lung cancer and colorectal cancer, often in combination with chemotherapy. Summit Therapeutics Inc. also maintains an anti-infectives program, including ridinilazole, an oral antibiotic candidate studied for Clostridioides difficile infection. Through these product and development efforts, Summit Therapeutics Inc. plays a role in precision medicine across cancer and infectious disease, with a focus on therapies intended to address difficult-to-treat conditions.
CEO Mr. Robert W. Duggan · 265 employees · United States · https://www.smmttx.com